XXXX in-situ and @entity1137 of the breast--a review.

@entity1 @entity1137 @entity3821 @entity5 @entity1893
OBJECTIVES: To determine the incidence of @entity5 (invasive carcinoma or @entity3821 ) in @entity1 diagnosed with @entity1137 (B3) on core needle biopsy (CNB) of breast lesions by reviewing the published literature. METHODS: Medline, Embase, OVID-database and reference lists were searched to identify and review all English-language articles addressing the management of LN diagnosed on CNB. Studies on mixed breast pathologies were excluded. RESULTS: Of 1229 LN diagnosed on CNB, 789 (64%) underwent surgical excision. 211 (27%) of excisions contained either @entity3821 or invasive disease. 280 of the excision specimens were classified as ALH, 241 as LCIS, 22 as @entity1893 and 246 unspecified LN on the original CNB. After surgical excision, 19% of the ALH cases, 32% of the LCIS cases and 41% of the PLCIS cases, contained @entity5 . 29% of the unspecified LNs were upgraded to @entity5 . The higher incidence of @entity5 within excision specimens for LCIS and PLCIS compared to ALH was significant (P  <  0.04, <0.003 respectively). CONCLUSION: There is a significant underestimation of @entity5 in @entity1 diagnosed with breast LN on CNB. 27% cases of CNB-diagnosed LN were found to contain @entity5 following surgical excision. All @entity1 diagnosed with LN on CNB should be considered for surgical excision biopsy.
